Send to

Choose Destination
J Neuroimmunol. 2013 Aug 15;261(1-2):123-8. doi: 10.1016/j.jneuroim.2013.05.009. Epub 2013 Jun 22.

Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab.

Author information

Tisch Multiple Sclerosis Research Center of New York, 521 West 57th Street 4th Fl., New York, NY 10019, USA.


Progressive multifocal leukoencephalopathy (PML) is a complication of natalizumab treatment. In order to identify natalizumab-treated patients at risk of developing PML, we assayed for anti-JC virus (JCV) antibody levels in cerebrospinal fluid (CSF). Serial CSF antibody levels were obtained, with 4 patients showing increases in anti-JCV levels indicating possibly viral activation. In patients with both CSF and serum antibody levels, a comparison showed only a moderate Spearman Rank Correlation Coefficient of 0.38. Our data suggests that serum anti-JCV antibody testing alone may not suffice in identifying at-risk patients because of the lack of uniform correlation with CSF titers.


Cerebrospinal fluid; JCV; Multiple sclerosis; Natalizumab; PML; Tysabri

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center